AtriCure Inc. (ATRC) Stake Lowered by Millennium Management LLC

Millennium Management LLC decreased its position in shares of AtriCure Inc. (NASDAQ:ATRC) by 60.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 336,972 shares of the medical device company’s stock after selling 522,899 shares during the quarter. Millennium Management LLC’s holdings in AtriCure were worth $9,115,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Highbridge Capital Management LLC acquired a new position in AtriCure during the 1st quarter worth $208,000. JPMorgan Chase & Co. lifted its holdings in AtriCure by 105.1% during the 1st quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock worth $292,000 after buying an additional 7,281 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in AtriCure during the 2nd quarter worth $301,000. BlueMountain Capital Management LLC lifted its holdings in AtriCure by 121.8% during the 2nd quarter. BlueMountain Capital Management LLC now owns 14,904 shares of the medical device company’s stock worth $403,000 after buying an additional 8,184 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in AtriCure by 135.4% during the 2nd quarter. GSA Capital Partners LLP now owns 26,054 shares of the medical device company’s stock worth $705,000 after buying an additional 14,984 shares in the last quarter. 90.77% of the stock is currently owned by hedge funds and other institutional investors.

ATRC has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price objective (up previously from $32.00) on shares of AtriCure in a report on Thursday, August 2nd. Zacks Investment Research raised AtriCure from a “sell” rating to a “hold” rating in a report on Friday, August 24th. ValuEngine raised AtriCure from a “buy” rating to a “strong-buy” rating in a report on Friday, August 3rd. BTIG Research reaffirmed a “hold” rating on shares of AtriCure in a report on Thursday, August 2nd. Finally, Stifel Nicolaus upped their price objective on AtriCure from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. AtriCure currently has an average rating of “Buy” and an average target price of $33.00.

In other AtriCure news, SVP Justin J. Noznesky sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $30.32, for a total transaction of $121,280.00. Following the completion of the sale, the senior vice president now owns 124,920 shares in the company, valued at approximately $3,787,574.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.70% of the company’s stock.

NASDAQ:ATRC opened at $33.02 on Monday. AtriCure Inc. has a 52-week low of $14.88 and a 52-week high of $36.49. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.37 and a current ratio of 3.16. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -39.78 and a beta of 0.17.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, August 1st. The medical device company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. The company had revenue of $51.80 million during the quarter, compared to analysts’ expectations of $49.94 million. AtriCure had a negative net margin of 10.85% and a negative return on equity of 16.57%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.21) EPS. On average, analysts expect that AtriCure Inc. will post -0.89 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Featured Article: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply